

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on July 13, 2009

PATENT  
Attorney Docket No.: 015270-008920US

TOWNSEND and TOWNSEND and CREW LLP

By: 

Tina Trieu

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Dale B. Schenk et al.

Application No.: 10/699,517

Filed: October 31, 2003

For: PREVENTION AND TREATMENT  
OF SYNUCLEINOPATHIC DISEASE

Customer No.: 20350

Confirmation No.: 8113

Examiner: Daniel E. Kolker

Art Unit: 1649

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In compliance with the requirements of 37 CFR §1.98(a)(2); copies of the non US patent cite nos. 240-247, and 255 are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant cites the following applications which are directed to related subject matter and are commonly owned or under an assignment obligation to be commonly owned by Elan Pharmaceuticals, Inc. and The Regents of the University of California:

60/984,721 filed 11/01/2007;

11/842,054 filed 08/20/2007;  
11/697,646 filed 04/06/2007;  
11/710,248 filed 02/23/2007;  
11/185,907 filed 07/19/2005 published as 2006/0058233 on 03/16/2007;  
10/915,214 filed 08/09/2004 published as 2005/0037013 on 02/17/2005;  
10/698,099 filed 10/31/2003 published as 2004/0146521 on 07/29/2004; and  
10/699,517 filed 10/31/2003 published as 2004/0136993 on 07/15/2004.

Applicant also cites the following applications directed to related subject matter but subject to different assignment:

11/194,115 filed 07/29/2005; issued as U.S. 7,358,331 on 04/15/2008;  
10/984,192 filed 11/08/2004 published as 2005/0196818 on 09/08/2005;  
10/969,335 filed 10/19/2004; issued as U.S. 7,306,945 on 12/11/2007;  
10/850,570 filed 05/19/2004 abandoned 09/26/2004;  
60/518,140 filed 11/08/2003; and  
60/471,929 filed 05/19/2003.

Applicant further cites the following commonly owned abandoned applications or abandoned applications under an assignment obligation to be commonly owned which are directed to related subject matter:

11/660,015 filed 02/09/2007 (U.S. Nat'l Stage entry of PCT/US05/28166);  
11/894,772 filed 08/20/2007;  
11/841,996 filed 08/20/2007;  
11/894,605 filed 08/20/2007;  
11/894,744 filed 08/20/2007; and  
60/423,012 filed 11/01/2002.


Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining

papers from that source he or she are invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Rosemarie L. Celli". The signature is fluid and cursive, with the first name "Rosemarie" being more prominent than the last name "Celli".

Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC:t4t  
62120984 v1